Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent.~* Age ≥ 18 years.~* Both sexes.~* Postoperative cataract surgery by phacoemulsification. o That they have met the criteria for phacoemulsification and a classification of the lens opacity classification system (LOCS) III cataract of Opalescence of the nucleus (NO) ≥2 and Kernel color (NC) ≥2.~Exclusion Criteria:~* Pregnant women, lactating or planning to get pregnant.~* Women of reproductive age and who do not have a hormonal contraceptive method, intrauterine device or bilateral tubal obstruction.~* Participation in another clinical research study ≤ 30 days before the baseline visit.~* Have previously participated in this same study with the contralateral eye.~* That they can not comply with their attendance at appointments or with all the requirements of the protocol.~Medical and therapeutic criteria.~* Surgery in both eyes in the same surgical shift.~* Time\> 24 hours after having surgery.~* Intraocular lens placement outside the bag.~* Presentation of rupture of the posterior capsule, with or without the presence of vitreous.~* Carrying out an iridectomy, or lesion of the pupillary sphincter during phacoemulsification surgery.~* Scheduled for surgical intervention in the contralateral eye during the study period.~* History of glaucoma or ocular hypertension.~* History of increased Intraocular pressure (IOP) with the use of steroids.~* Intraocular pressure (IOP) ≥24.~* History of uveitis.~* Presence of corneal abrasion or corneal ulceration in the study eye.~* Use of steroids or topical non steroidal anti inflammatory drugs, 24 hours prior to surgery and until the start of instillation of investigational drugs.~* Use of anticoagulants, systemic steroids or immunomodulators in the last two weeks~* Periocular injection of any steroid in the study eye 4 weeks before the start of the instillation of the investigational drugs.~* Use of storage steroids 2 months prior to the start of instillation of investigational drugs.~* Presence or suspicion of keratitis and / or viral, bacterial or fungal conjunctivitis.~* Presence or suspicion of endophthalmitis.~* Presence or suspicion of toxic syndrome of the anterior segment.~* Severe corneal edema that does not allow assessment of the anterior chamber~* Macular diseases.~* Diabetes Mellitus with glycosylated hemoglobin (A1C) ≥ 6.5% (48 mmol / mol) or fasting glucose (no caloric intake by ≥ 8 hours) of ≥ 126 mg / dL (7.0 mmol / L).~* Any disease or condition that requires the use of topical or systemic nonsteroidal anti-inflammatories (NSAIDs) during the time of intervention.~* Any disease or condition that requires the use of steroids other than topical ophthalmic application.~* Subjects with a single eye.~* Any condition or disease that at the discretion of the principal investigator (IP) does not make the subject suitable for the study.~* Known hypersensitivity to the components of the products under investigation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PRO-145. (Type: EXPERIMENTAL): Difluprednate 0.05%. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
- Prednefrin (Type: ACTIVE_COMPARATOR): Prednefrin® SF. Prednisolone Acetate 1%. Prepared by Allergan, S.A. of C.V.

Based on this trial design, predict the completion outcome and termination type (if applicable).